The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...

GSK and Alfasigma ink agreement on worldwide rights for linerixibat, an IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis: London, UK Tuesday, March 10, 2026, ...

GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy ...

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

Protein aggregates as hallmarks of severe alcohol-related liver injuryAlcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and ...

Delhi doctors warn of severe health risks from contaminated water, especially for vulnerable groups, amid rising cases of water-borne diseases.

Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.

A new study of 12 million newborns found that a routine birth dose vaccine is rapidly losing ground across US hospitals. | ...

Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA coul | Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve ...

Under the terms of the agreement, Alfasigma is expected to acquire worldwide exclusive rights to develop, manufacture and commercialize linerixibat, while GSK will receive an upfront payment of $300 ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...